EFX
77
2
C
50
2
MAR
42
-2
RSG
60
-10
THC
73
3
HAL
54
4
QCOM
55
-2
VNO
50
3
GD
60
4
AMAT
49
-3
BIIB
37
2
ESS
64
-3
HOG
45
7
AVGO
25
-2
MDLZ
48
-2
HUM
49
3
PX
58
3
DHR
57
-9
STI
24
-2
ABBV
68
4
EFX
77
2
C
50
2
MAR
42
-2
RSG
60
-10
THC
73
3
HAL
54
4
QCOM
55
-2
VNO
50
3
GD
60
4
AMAT
49
-3
BIIB
37
2
ESS
64
-3
HOG
45
7
AVGO
25
-2
MDLZ
48
-2
HUM
49
3
PX
58
3
DHR
57
-9
STI
24
-2
ABBV
68
4
Financhill
Back

Perspective Therapeutics 10K Form

Buy
65

CATX
Perspective Therapeutics

Last Price:
13.71
Seasonality Move:
0.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CATX News And Ratings

See the #1 stock for the next 7 days that we like better than CATX

CATX Financial Statistics

Sales & Book Value

Annual Sales: $3.55M
Cash Flow: $4.78M
Price / Cash Flow: 0
Annual Sales: $3.92
Price / Book: 3.99

Profitability

EPS (TTM): -1.90000
Net Income (TTM): $-58.42M
Gross Margin: $817K
Return on Equity: 0%
Return on Assets: 0%

Perspective Therapeutics Earnings Forecast

Key Perspective Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 29 years for CATX is 23.00%.
  • The Selling, General & Administrative Expenses for CATX have been equal to 200.08% of Gross Profit Margin.
  • The Interest Expense is -0.18% of Operating Income.
  • Per Share Earnings over the last 30 years have been positive in 16 years.

Perspective Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: CATX
Website: perspectivetherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CATX Technical Analysis vs Fundamental Analysis

Buy
65
Perspective Therapeutics (CATX) is a Buy

Is Perspective Therapeutics a Buy or a Sell?